One To Watch
MacroGenics
Company Overview
A Maryland-based oncology-focused biotech developing antibody-based therapeutics using proprietary bispecific and ADC platforms, with one approved PD-1 inhibitor and a Gilead-partnered bispecific CD123xCD3 program in clinical development. MacroGenics discovers, develops, manufactures, and commercializes innovative antibody-based therapeutics primarily targeting cancer. The company's commercial asset, Zynyz (retifanlimab-dlwr), provides a revenue base while the pipeline advances through multiple partnerships. In May 2026, MacroGenics divested its GMP manufacturing arm to Bora Pharmaceuticals for $122.5 million, reflecting a strategic pivot toward a leaner, pipeline-focused operating model.
Headquarters and Global Presence
MacroGenics is headquartered in Rockville, Maryland, USA. The company operates primarily in the United States, with commercial and clinical activities extending internationally through partnership agreements with Incyte, Gilead Sciences, and others.
Founding and History
MacroGenics was founded in 2000 and built its early reputation around proprietary Fc-optimization and bispecific antibody engineering. The company achieved a significant regulatory milestone with the FDA approval of Margenza (margetuximab-cmkb) for HER2-positive metastatic breast cancer, its first approved oncology product. Zynyz subsequently became the company's primary commercial asset, partnered with Incyte, which paid a $100 million milestone in July 2024. Eric Risser was appointed president and CEO in August 2025, marking a leadership transition as the company restructures operations.
Therapy Areas and Focus
MacroGenics focuses principally on oncology, targeting hematologic malignancies and solid tumors where standard-of-care options remain inadequate. Zynyz, a PD-1 inhibitor, addresses immuno-oncology indications in partnership with Incyte. The company's pipeline extends into bispecific T-cell engager approaches for blood cancers and ADC strategies for solid tumors, reflecting a multi-modality oncology strategy. Historically, MacroGenics also explored autoimmune disease but has divested or wound down those programs to concentrate on cancer.
Technology Platforms and Modalities
MacroGenics' core proprietary platform is DART (Dual-Affinity Re-Targeting), which enables the engineering of bispecific antibodies capable of simultaneously binding two distinct targets — most critically pairing a tumor antigen with CD3 on T cells to redirect cytotoxic killing. The Fc-optimization technology underpins margetuximab and enhances antibody-dependent cellular cytotoxicity. MacroGenics also pursues antibody-drug conjugates, exemplified by vobramitamab duocarmazine, which links a B7-H3-targeting antibody to a DNA-alkylating duocarmycin payload. Together these platforms span immune checkpoint blockade, T-cell engagement, and targeted cytotoxic delivery.
Key Pipeline and Programs
Zynyz (retifanlimab-dlwr) is an anti-PD-1 monoclonal antibody approved and commercialized in partnership with Incyte, generating milestone and royalty revenue for MacroGenics; a royalty purchase agreement with Sagard Healthcare was expanded in May 2026 to monetize future global net sales.
MGD024 is a bispecific antibody built on the DART platform that simultaneously targets CD123, overexpressed on acute myeloid leukemia and other hematologic malignancies, and CD3 to redirect T-cell cytotoxicity. Gilead Sciences entered an exclusive option and collaboration agreement worth up to $1.7 billion in June 2024 to develop MGD024 alongside two additional bispecific research programs, underscoring the asset's perceived value in AML and related blood cancers.
Vobramitamab duocarmazine (vobra duo) is a B7-H3-directed ADC carrying a duocarmycin payload investigated in solid tumors. Development was paused in November 2024 following safety concerns — including treatment-related deaths in the Phase II TAMARACK study — prompting a strategic review of its path forward. MacroGenics also entered an expanded ADC collaboration with Synaffix in June 2024 to broaden the B7-H3 ADC program's technical foundation.
Recent Developments
In May 2026, MacroGenics agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million upfront, a move designed to reduce operating costs and redirect capital to the clinical pipeline. That same month, MacroGenics expanded its royalty monetization arrangement with Sagard Healthcare on Zynyz, sending shares up nearly 8% on the announcement. Eric Risser was elevated to president and CEO in August 2025, succeeding prior leadership as the company navigates a leaner organizational model. The Gilead collaboration on MGD024, announced in June 2024 at up to $1.7 billion in potential value, remains the most strategically significant recent partnership.
Key Personnel
Eric Risser serves as President and Chief Executive Officer, having been promoted to the role in August 2025 and appointed concurrently to the board of directors. He brings operational and commercial experience from within MacroGenics' leadership ranks. The company's scientific foundation draws on a seasoned antibody engineering team that developed both the DART bispecific platform and its Fc-optimization technology over more than two decades.
Strategic Partnerships
The Gilead Sciences collaboration on MGD024 and two additional bispecific programs, valued at up to $1.7 billion, is MacroGenics' most significant active deal. Incyte commercializes Zynyz globally and has paid at least $100 million in milestones to MacroGenics as of July 2024. MacroGenics' expanded royalty purchase agreement with Sagard Healthcare on Zynyz provides near-term liquidity in exchange for a capped royalty interest. Synaffix, a Dutch ADC specialist, holds an enhanced collaboration agreement supporting MacroGenics' B7-H3 ADC work.
FAQ Section
The $122.5 million sale of GMP manufacturing operations to Bora Pharmaceuticals in May 2026 reflects MacroGenics' deliberate shift toward an asset-light model, preserving cash for clinical programs rather than maintaining capital-intensive infrastructure. The move follows earlier royalty monetization deals — including the Sagard Healthcare arrangement on Zynyz and the $200 million sale of Tzield royalties — indicating a sustained effort to fund the pipeline through asset sales rather than equity dilution. With Gilead now backing MGD024, the rationale for owning manufacturing in-house has diminished significantly.
CD123, the interleukin-3 receptor alpha chain, is overexpressed on leukemic stem cells and blasts in acute myeloid leukemia, myelodysplastic syndromes, and blastic plasmacytoid dendritic cell neoplasm — malignancies with poor prognoses and limited targeted options. By co-engaging CD123 on tumor cells and CD3 on cytotoxic T cells, DART-based bispecifics like MGD024 redirect endogenous immune killing without requiring patient T-cell pre-activation. Gilead's willingness to commit up to $1.7 billion to the program reflects the high commercial potential of a validated T-cell engager in AML.
The DART platform uses a diabody-based scaffold that positions two antigen-binding domains in close proximity, producing a compact, stable bispecific molecule with potent dual-target engagement. Unlike some bispecific formats that rely on IgG-based asymmetric engineering prone to mispairing, DART molecules are engineered for clean heterodimerization and consistent manufacturing. MacroGenics has applied the platform across multiple immunological axes — CD123xCD3 in hematology, and previously CD19xCD3 with Janssen — demonstrating platform versatility.
Development of vobramitamab duocarmazine was placed on hold in November 2024 following safety data from the Phase II TAMARACK study, which showed treatment-related deaths even at a reduced dose. The concerns center on the duocarmycin payload's narrow therapeutic window, a challenge common to DNA-alkylating ADC payloads. MacroGenics has not formally discontinued the program, but no near-term resumption has been announced, and strategic attention has shifted toward MGD024 and Zynyz.
Oncology is the exclusive focus, spanning both hematologic malignancies and solid tumors. In blood cancers, MGD024 targets AML and related diseases through T-cell redirection. In solid tumors, the B7-H3-directed ADC program addresses a broadly expressed tumor antigen present across multiple carcinomas. MacroGenics has divested or wound down its earlier autoimmune assets, including the Takeda-optioned MGD010 and the Provention Bio-licensed programs, making oncology the company's singular strategic commitment.
MacroGenics is a late-clinical to commercial-stage company: Zynyz is approved and generating royalties, while MGD024 advances through early-to-mid clinical development under the Gilead collaboration. The most consequential near-term milestone is clinical data from MGD024 in AML, which will shape Gilead's decision on whether to exercise its option and proceed toward Phase III. The vobra duo program requires a resolution — either a redesigned trial or discontinuation — before it can re-enter the catalysts horizon.
Key watchpoints include:
- MGD024 Phase I/II data readouts in AML and the timing of Gilead's option exercise decision, which could trigger substantial milestone payments
- Zynyz commercial trajectory and Incyte's ability to expand indications, underpinning royalty streams sold to Sagard
- Resolution of the vobra duo safety questions — whether a revised dosing strategy can rehabilitate the program or whether it is formally shelved
- Deployment of the $122.5 million from the Bora manufacturing sale and whether it provides sufficient runway to reach MGD024 data milestones without further dilution
- Leadership continuity under new CEO Eric Risser and the strategic direction he sets for the restructured company
Latest MacroGenics News
Today's issue
| Headless Content Management with Blaze